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Abstract
RASSF1A [Ras association (RalGDS/AF-6) domain family member 1A] and RASSF1C are two 
ubiquitously expressed isoforms of the RASSF1 gene. The promoter of RASSF1A is frequently 
hypermethylated, resulting in inactivation in various human cancers. RASSF1A is implicated in 
the regulation of apoptosis, microtubule stability and cell cycle arrest. However, little is known 
about the regulation and function of RASSF1C. In the present study we show that exogenously 
expressed RASSF1C is a very unstable protein that is highly polyubiquitylated and degraded via 
the proteasome. Furthermore, RASSF1C degradation is enhanced when cells are exposed to stress 
signals, such as UV irradiation. Mule, a HECT (homologous with E6-associated protein C-
terminus) family E3 ligase, but not SCFβ-TrCP [where SCF is Skp1 (S-phase kinase-associated 
protein 1)/cullin/F-box and β-TrCP is β-bransducin repeat-containing protein] or CUL4 (cullin 4)-
DDB1 (damage-specific DNA-binding protein 1), is the E3 ligase for RASSF1C under normal 
conditions, whereas both Mule and SCFβ-TrCP target RASSF1C degradation in response to UV 
irradiation. GSK3 (glycogen synthase kinase 3) phosphorylates RASSF1C to promote RASSF1C 
degradation subsequently, which is negatively regulated by the PI3K (phosphoinositide 3-
kinase)/Akt pathway. Thus the present study reveals a novel regulation of RASSF1C and the 
potentially important role of RASSF1C in DNA damage responses.
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INTRODUCTION
RASSF1 [Ras association (RalGDS/AF-6) domain family member 1] is located in 
chromosome 3p21.3, which frequently undergoes loss of heterozygosity in human tumours 
[1,2]. RASSF1A and RASSF1C, two major isoforms of the tumour suppressor RASSF1, are 
transcribed from two different promoters and are expressed in most normal human tissues 
[3,4]. RASSF1A and RASSF1C are identical in their C-terminal domains, containing a Ras-
association domain, a SARAH (Sav/RASSF/Hpo) domain and an ATM (ataxia 
telangiectasia mutated) domain. RASSF1A has a 119 amino acid N-terminal region 
containing a cysteine-rich diacylglycerol-binding C1 domain, whereas RASSF1C has a 49 
amino acid N-terminal region without a C1 domain [5]. The identities and differences in the 
amino acid sequences of RASSF1A and RASSF1C indicate they may have different 
physiological and pathological functions.
RASSF1A, but not RASSF1C, has been shown to block cell cycle progression and inhibit 
cyclin D1 accumulation [6], and regulate mitosis by inhibiting the APC (anaphase-
promoting complex)–Cdc20 complex [7]. Both RASSF1A and RASSF1C are associated 
with microtubules, but only RASSF1A stabilizes microtubules [8,9]. In addition, RASSF1A 
has been implicated in the regulation of apoptosis [10,11], growth suppression [4] and DNA 
damage responses [12]. Compared with RASSF1A, the functions of RASSF1C are 
contradictory in different reports. Li et al. [13] showed that RASSF1C inhibited the 
proliferation of different cancer cell lines, such as LNCaP and KRC/Y; Vos et al. [14] 
reported that RASSF1C mediated Ras-dependent apoptosis in NIH 3T3 cells. However, 
RASSF1C has also been shown to promote osteoblast cell proliferation and breast cancer 
cell migration [15,16]. In contrast, Shivakumar et al. [6] showed that overexpression of 
RASSF1C did not affect proliferation of several different cell lines. Moreover, RASSF1C, 
but not RASSF1A, has been shown to release from the nucleus when DAXX (death-domain-
associated protein) is degraded in response to UV irradiation [17]. Therefore the functions of 
RASSF1C remain largely unknown and are worth further investigation.
Hypermethylation of the RASSF1A promoter is a very common event in various human 
cancers, including small cell lung cancer, non-small cell lung cancer, breast cancer, bladder 
cancer, primary nasopharyngeal cancer and primary renal cell carcinoma [3,4,18–22]. 
Interestingly, no detection of hypermethylation of the RASSF1C promoter has been 
reported, despite RASSF1C mRNA having been detected in many human cancers and 
cancer cell lines via Northern blot or qPCR (quantitative PCR). Why cancer cells need to 
epigenetically inactivate RASSF1A but not RASSF1C is an open question in this field. One 
possibility is that RASSF1A and RASSF1C might have very different functions. Indeed, 
Reeves et al. [16] proposed RASSF1C might be an oncogene. The other possible reason is 
that RASSF1C might be mainly regulated by post-translational events, which leads to low 
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activity or decreased protein levels in tumorigenesis. Due to a commercial anti-RASSF1C 
antibody which can detect endogenous RASSF1C expression being unavailable, most 
studies on RASSF1C regulation have been limited to the transcriptional level.
In the present study, we showed that RASSF1C is a very unstable protein that responds to 
different stress signals such as UV damage. Furthermore, we define Mule, but not SCFβ-TrCP 
[where SCF is Skp1 (S-phase kinase-associated protein 1)/cullin/F-box and β-TrCP is β-
transducin repeat-containing protein] or CUL4 (cullin 4)-DDB1 (damage-specific DNA-
binding protein 1), as a bona fide RASSF1C E3 ligase under normal conditions, whereas 
both Mule and SCFβ-TrCP are RASSF1C E3 ligases in response to UV irradiation. Moreover, 
RASSF1C phosphorylation by GSK3 (glycogen synthase kinase 3) promotes the interaction 
between RASSF1C and the E3 ligase Mule, thus leading to RASSF1C polyubiquitylation 
and degradation. The present study reveals a novel mechanism of RASSF1C regulation and 
implies a potentially important role of RASSF1C in DNA damage responses.
EXPERIMENTAL
Plasmid construction
Full-length cDNAs of RASSF1C were cloned into the pCDNA3-HA (haemagglutinin), 
pRK7-N-FLAG or pQCXIH vector using standard protocols. Ubiqutin, β-TrCP and GSK3β 
were cloned into the pCDNA3-HA vector.
Cell culture and transfection
HEK-293T [human embryonic kidney-293 cells expressing the large T-antigen of SV40 
(simian virus 40)] and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
(Invitrogen) supplemented with 10% fetal bovine serum (HyClone), 100 units/ml penicillin 
and 100 µg/ml streptomycin (Gibco). U2OS cells were maintained in RPMI 1640 medium 
(Invitrogen) supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 
µg/ml streptomycin. Cell transfection was performed using the calcium phosphate method or 
Lipofectamine™ 2000 (Invitrogen). Cells were harvested at 30 h post-transfection for 
protein analysis.
To establish stable RASSF1C-expressing cell pools, pQCXIH-SBP (streptavidin-binding 
peptide)-FLAG-RASSF1C retroviruses were generated and used to infect HEK-293T, HeLa 
and U2OS cells, and stable pools were selected with 50 mg/ml hygromycin B (Amresco) for 
5 days.
SBP purification of RASSF1C protein complexes
Ten 15 cm plates of HEK-293T SBP-FLAG-RASSF1C stable cells were pretreated with 
MG132 for 6 h before harvest, and then lysed in 40 ml of 0.5% Nonidet P40 buffer (50 mM 
Tris/HCl, pH 7.5, 150 mM NaCl and 0.5% Nonidet P40) containing 10 mM NaF, 1 mM 
Na3VO4 and protease inhibitor mixture (Roche) for 30 min. SBP-FLAG-RASSF1C in the 
supernatant was precipitated for 3 h with 100 µl streptavidin resin (GE HealthCare, 17–
5113-01), which was then washed three times with 0.5% Nonidet P40 buffer followed by 
three washes with 50 mM NH4HCO3. The precipitated protein was digested with trypsin as 
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described previously [45]. The supernatant was collected, dried and dissolved in 10% 
acetonitrile and 0.8% formic acid solution. The peptides were analysed by LC-MS/MS 
(liquid chromatography-tandem MS).
Immunoprecipitation and Western blotting analysis
Cells were lysed in 0.5 % Nonidet P40 buffer containing protease and phosphatase 
inhibitors. Cell debris was removed by centrifugation and the lysates were incubated for 3 h 
at 4°C with anti-FLAG M2 agarose (Sigma). The immunoprecipitates were washed four 
times with 0.5 % Nonidet P40 buffer and then analysed by Western blot. Antibodies against 
FLAG (A00170, GenScript or A2220, Sigma), HA (F7) (SC7392, Santa Cruz 
Biotechnology), DAXX (4533, Cell Signaling Technology), β-catenin (9562, Cell Signaling 
Technology) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase; SC32233, Santa 
Cruz Biotechnology) were purchased commercially. Anti-RASSF1C antibody was raised in 
rabbits using a synthetic peptide (CSQEDSDSE) as an antigen by Shanghai Genomics.
DNA-damaging stimuli
U2OS RASSF1C stable cells were cultured to approximately 70–80 % confluence in 35-
mm-diameter dishes and were irradiated with 40 mJ/cm2 UVC delivered via a HL-2000 
HybriLinker with a 254 nm wavelength (Upvon), followed by the indicated recovery time 
before harvest to analyse RASSF1C protein levels or cellular localization.
Cytoplasmic and nuclear extracts
One 10-cm-diameter plate of U2OS stable cells were lysed in 1 ml Harvest buffer (10 mM 
Hepes, pH 7.9, 50 mM NaCl, 0.5 M sucrose, 0.1 mM EDTA, 0.5% Triton X-100 and freshly 
added protease and phosphatase inhibitors) at 4°C for 10 min, and then centrifuged at 500 g 
for 10 min to pellet the nucleus. The pellet was then washed three times with washing buffer 
(10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA and freshly added 
protease and phosphatase inhibitors). The supernatant was subjected to 17 000 g 
centrifugation for another 10 min to remove any nuclear contamination and transferred to a 
new tube. Both the pellet and supernatant were boiled seperately in SDS sample buffer.
RNAi (RNA interference)
RNAi-mediated down-regulation of Mule was performed by either transfecting Mule siRNA 
(small interfering RNA) or control siRNA into HEK-293T or U2OS RASSF1C stable cells 
following the manufacturer’s instructions for Lipofectamine™ RNAiMAX reagent (904203, 
Invitrogen). The knockdown effects were assessed 48 h after induction of RNAi. The siRNA 
sequences were as follows: siMule#1, 5′-GAGUUUGGAGUUUGUGAAGTT-3′; siM-
ule#2, 5′-AAUUGCUAUGUCUCUGGGACA-3′; siControl, 5′-
AAUUGCCAUGUAUCUGGGACA-3′; and siDDB1, 5-CCUG-
UUGAUUGCCAAAAAC-3′.
RNA isolation and real-time PCR
Total cellular RNA was isolated from cultured cells using TRIzol® reagent following the 
manufacturer’s instructions (Invitrogen). RNA was reverse transcribed with oligo(dT) 
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primers and realtime PCR was conducted with gene-specific primers in the presence of 
SYBR Premix Ex Taq (TaKaRa). qPCR was performed in triplicate, using GAPDH as a 
housekeeping control. Relative fold changes in the expression of Mule in control and Mule-
knockdown cells were determined using the ΔΔCt method.
The primer sequences used were: RASSF1C forward, 5′-GC-
TACTGCAGCCAAGAGGAC-3′; RASSF1C reverse, 5′-AGGT-
GTCTCCCACTCCACAG-3′; Mule forward, 5′-ACAACCT-CGAGCAGCAGCGG-3′; 
Mule reverse, 5′-TTGTTAGCCCG-GCGCGTGTC-3′; GAPDH forward, 5′-
GATGACATCAAGAA-GGTGGTGAAG-3′; and GAPDH reverse, 5′-TCCTTGGA-
GGCCATGTGGGCCAT-3′.
RESULTS
RASSF1C protein decreases in response to DNA damage
A previous study showed that DAXX underwent polyubiquitylation and degradation to 
promote RASSF1C release from the nucleus in response to DNA damage in HeLa cells [17]. 
This triggered us to test the effect of DNA damage on RASSF1C regulation. Surprisingly, 
we found both cytosolic and nuclear RASSF1C protein levels reduced significantly when 
U2OS cells were treated with UV irradiation (Figure 1A). The protein levels of RASSF1C 
decreased in a time-course-dependent manner in response to UV irradiation (Figures 1B and 
1C). Interestingly, we found the levels of RASSF1C reduced by half in 15 min, which is 
much faster than DAXX or RASSF1A (Figure 1B). These results indicated that the nuclear 
RASSF1C reduction may not be due to release into the cytosol after DAXX degradation, but 
mediated by an unknown mechanism. Although we did not observe the translocation of 
RASSF1C in response to UV irradiation, we cannot rule out the different results of the 
present study compared with previous work [17] due to the different cell lines or the dose of 
UV used.
We also analysed RASSF1C protein levels when cells were exposed to a variety of stresses. 
Interestingly, treatment with doxorubicin, osmotic stress or serum starvation also reduced 
the protein levels of RASSF1C in a time-course-dependent manner (Figure 1D, upper panel, 
and Supplementary Figures S1A and S1B at http://www.BiochemJ.org/bj/441/
bj4410227add.htm).
The possible reasons for UV-induced decrease of RASSF1C may be due to the transcription 
or protein stability of RASSF1C. To this end, we employed qPCR and found that the mRNA 
levels of RASSF1C changed little in comparison with the dramatic down-regulation of 
protein levels (Figures 1C and 1D, lower panels). Thus the decrease of RASSF1C induced 
by UV irradiation and doxorubicin might not due to transcriptional regulation.
RASSF1C stability is regulated by the 26S proteasome
These results promoted us to test whether the proteasome is involved in RASSF1C protein 
degradation. We treated HEK-293T and HeLa stable cells with the protein synthesis 
inhibitor CHX (cycloheximide) and measured the half-life of RASSF1C. Remarkably, we 
found that RASSF1C is a very unstable protein with a half-life of approximately 15 min, 
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indicating the functional importance of this protein (Figure 1E and Supplementary Figure 
S2A at http://www.BiochemJ.org/bj/441/bj4410227add.htm). Treatment of the two stable 
cells with the proteasome inhibitor MG132 also increased the steady-state level of 
RASSF1C by 5-or 16-fold in HEK-293T or HeLa cells respectively (Figure 1F and 
Supplementary Figure S2B). Furthermore, we determined the polyubiquitylation of 
RASSF1C in vivo. Prior to the analysis of RASSF1C polyubiquitylation, cells were treated 
with MG132 to enrich polyubiquitylated proteins. Co-expression of RASSF1C with 
ubiquitin resulted in the detection of characteristic incremental ladders, the indicative of 
polyubiquitylated species (Figure 1G). Collectively, our data suggests that RASSF1C 
protein stability is regulated by the proteasome and may respond to DNA damage.
SCFβ-TrCP and CUL4-DDB1 are not involved in RASSF1C degradation under normal 
conditions
Proteasome-mediated degradation depends on polyubiquitylation of target proteins. A direct 
interaction between the E3 ubiquitin ligase and target protein indicates the selective 
polyubiquitylation of the target protein. To search for RASSF1C-interacting proteins, we 
performed MS analysis of affinity-purified RASSF1C (Figure 2A). The candidate 
degradation-related RASSF1C-interacting proteins identified in this search are shown in 
Figure 2(B).
Interestingly, CUL1, Skp1, β-TrCP1 and β-TrCP2 were identified in a potential RASSF1C-
interacting protein complex. These identified peptides are shown in Supplementary Table S1 
(at http://www.BiochemJ.org/bj/441/bj4410227add.htm). CUL1, Skp1, β-TrCP1 and β-
TrCP2, which belong to the SCF class of E3 ubiquitin ligase, have been implicated in the 
degradation of many growth-promoting proteins, such as IκB (inhibitory κB), β-catenin and 
Emi1 (early mitotic inhibitor 1) [23]. To confirm the interaction between RASSF1C and the 
SCFβ-TrCP E3 ligase complex, we performed co-immunoprecipitation experiments and 
found that both β-TrCP1 and β-TrCP2 could be readily pulled down by RASSF1C (Figure 
2C) as described previously [24]. β-TrCP can recognize the D/SpSGXXpS phosphodegron 
of target proteins, and phosphorylation of this phosphodegron generates the binding sites for 
SCFβ-TrCP and subsequently leads to proteasome degradation. RASSF1C contains the 
SSGYCS degron, and we generated the S19A/S23A phosphodegron mutant to determine 
whether this mutant could disrupt the interaction. As expected, the S19A/S23A mutant 
dramatically decreased the interaction between RASSF1C and β-TrCP1 (Figure 2C, left-
hand panel) or β-TrCP2 (Figure 2C, right-hand panel).
On the basis of this data, we believed that the S19A/S23A mutant should be resistant to 
proteasome-mediated degradation. To our surprise, MG132 treatment still led to obvious 
RASSF1C accumulation (Figure 2D) and the half-life of S19A/S23A mutant is the same as 
wild-type RASSF1C (Figure 2E). Furthermore, β-TrCP1 overexpression didn’t result in an 
increase of characteristic ladders (Figure 2F). Moreover, the S19A/S23A mutant retained the 
same amount of polyubiquitin ladders (Figure 2G). Taken together, these results suggest that 
SCFβ-TrCP is not the potential E3 ligase for RASSF1C degradation under normal conditions.
The ROC1-CUL4-DDB1 E3 ligase is reported to regulate chromatin formation, cell cycle 
checkpoint, DNA replication and DNA damage responses [25]. As shown in Figure 2(B), 
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CUL4A and DDB1 were also coimmunoprecipitated by RASSF1C. However, DDB1 
knockdown also didn’t lead to the accumulation of RASSF1C (see Supplementary Figure S3 
at http://www.BiochemJ.org/bj/441/bj4410227add.htm). Collectively, these results indicated 
that ROC1-CUL4-DDB1 is also not involved in the degradation of RASSF1C under normal 
conditions.
Mule promotes RASSF1C degradation under normal conditions
Given that SCFβ-TrCP and CUL4-DDB1 are not the potential E3 ligases responsible for 
RASSF1C degradation, we tested another potential E3 ligase, Mule, which was identified in 
our SBP affinity purification (Supplementary Table S2 at http://www.BiochemJ.org/bj/441/
bj4410227add.htm). Mule belongs to the HECT (homologous with E6-associated protein C-
terminus) family and ubiquitylates multiple proteins such as Mcl-1 and p53 [26–29]. The 
strong interaction between Mule and RASSF1C can be easily detected. Similarly, the 
catalytically inactive Mule mutant C4341A also strongly interacted with RASSF1C (Figure 
3A). As shown in Figure 3(B), two different Mule knockdown, but not control, 
oligonucleotides resulted in dramatic accumulation of RASSF1C. To prove that the Mule-
knockdown-induced accumulation of RASSF1C protein was due to decreased degradation, 
we analysed the half-life of RASSF1C in Mule knockdown or control cells. We observed 
that Mule knockdown HEK-293T cells displayed higher RASSF1C protein levels (Figure 
3B, left-hand panel) and the half-life of RASSF1C was prolonged from 15 min to longer 
than 30 min (Figure 3C), although the knockdown efficiency is only 50% (Figure 3B, right-
hand panel). Altogether, these results indicate that Mule promotes the proteasomal 
degradation of RASSF1C under normal conditions.
The PI3K (phosphoinositide 3-kinase)/Akt pathway inhibits GSK3 to upregulate RASSF1C 
protein levels
RASSF1A has been reported to undergo phosphorylation-induced degradation [30]. Given 
that RASSF1C is identical to RASSF1A except for 49 amino acids at the N-terminal, we 
hypothesized that phosphorylation regulation might also play a role in RASSF1C 
degradation. To test whether phosphorylation is involved in RASSF1C degradation, we 
examined the effect of the phosphatase inhibitor calyculin A on RASSF1C protein levels. 
Interestingly, we found calyculin A treatment led to the decrease of RASSF1C and the shift 
of the RASSF1C protein band, indicating the regulation of the phosphorylation of RASSF1C 
(Figure 4A). Furthermore, MG132 significantly blocked calyculin A-induced RASSF1C 
degradation (Figure 4B).
Interestingly, we found that RASSF1C contains a potential motif recognized by GSK3 using 
a motif scan (http://scansite.mit.edu/motifscan_seq.phtml). In addition, RASSF1A has been 
shown to be phosphorylated by GSK3β [31]. These led us to examine if GSK3 is responsible 
for RASSF1C phosphorylation. As shown in Figure 4(C), two different GSK3 inhibitors, but 
not a CK1 (casein kinase 1) inhibitor, resulted in RASSF1C accumulation, with β-catenin 
and TAZ (transcriptional coactivator with PDZ-binding motif) serving as positive controls 
respectively. When we examined the interaction between RASSF1C and GSK3β, RASSF1C 
readily pulled down GSK3β (Figure 4D). Furthermore, GSK3β overexpression led to the 
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decrease of RASSF1C. More importantly, this effect was totally blocked by MG132 (Figure 
4E).
GSK3 activity is regulated by different cell signalling pathways, such as the Wnt signalling 
pathway, the PI3K/Akt pathway and the MAPK (mitogen-activated protein kinase) pathway. 
To figure out which pathway is involved in the regulation of RASSF1C stability through 
GSK3, we treated cells with the PI3K inhibitor LY294002, and found that LY294002 led to 
decreased RASSF1C protein levels in a dose-dependent manner as shown in Figure 4(F). 
MG132 totally blocked LY294002-induced RASSF1C degradation (Figure 4G). Moreover, 
the GSK3 inhibitor SB216763 totally blocked RASSF1C degradation induced by LY294002 
and wortmannin (Figure 4H). More importantly, the interaction between Mule and 
RASSF1C can be blocked by SB216763 (Figure 4I). Collectively, GSK3β is the bona fide 
RASSF1C kinase, and phosphorylation regulation promotes RASSF1C degradation by 
enhancing the interaction between the E3 ligase and target protein. It would be worth further 
study to identify GSK3β-specific phosphorylation site(s) in RASSF1C.
DNA damage promotes the polyubiquitylation and degradation of RASSF1C
We have demonstrated that RASSF1C is a very unstable protein and can be 
polyubiquitylated by Mule, which promotes its proteasomal degradation. Notably, a variety 
of stresses, including UV irradiation, doxorubicin, osmotic stress and serum starvation can 
induce a decrease in RASSF1C protein levels (Figures 1C and 1D, and Supplementary 
Figures S1A and S1B). Thus we examined the effect of the proteasome inhibitor MG132 on 
stress-induced RASSF1C protein decrease. Interestingly, MG132 totally blocked DNA 
damage, osmotic stress and serum-starvation-triggered RASSF1C protein decrease (Figure 
5A, and Supplementary Figure S4 at http://www.BiochemJ.org/bj/441/bj4410227add.htm), 
indicating that DNA damage promotes RASSF1C degradation via the proteasome. As 
expected, UV irradiation and doxorubicin promoted the polyubiquitylation of RASSF1C 
(Figure 5B). Moreover, RASSF1C is mainly degraded in the nucleus, as we noticed that 
MG132 can totally block UV-induced degradation in the nucleus (Figure 5C). In addition, 
the interaction between RASSF1C and Mule was enhanced when cells were exposed to UV 
irradiation (Figure 5D, top panel). Furthermore, RASSF1C protein levels were halved in 15 
min in response to UV irradiation (as shown in Figures 1B and 5E), which was significantly 
delayed to 60 min when U2OS cells were transfected with Mule siRNA compared with 
control oligos (Figure 5E and Supplementary Figure S5 at http://www.BiochemJ.org/bj/441/
bj4410227add.htm). At the same time, we found that the S19A/S23A mutant, which disrupts 
the interaction between β-TrCP and RASSF1C, has a comparable effect with Mule 
knockdown under UV irradiation conditions (Figure 5F). Similarly, we found that UV 
irradiation significantly increases the interaction between β-TrCP and RASSF1C (Figure 
5D, bottom panel). However, DDB1 knockdown did not lead to resistance to UV-induced 
RASSF1C degradation (Supplementary Figure S3). Moreover, we found that the GSK3 
inhibitor SB216763 can also block UV-induced RASSF1C degradation (Figure 5G). 
Collectively, DNA damage promotes GSK3 phosphorylation of RASSF1C and subsequent 
polyubiquitylation and degradation via Mule and SCFβ-TrCP, but not via CUL4A–DDB1 E3 
ligase.
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The RASSF1 gene was first identified in a yeast two-hybrid screen for partners of the human 
DNA excision repair protein XPA (xeroderma pigmentosum A) [4]. Until now, numerous 
studies have demonstrated that RASSF1A plays a very important role in cancer development 
by regulating cell cycle arrest, microtubule stability and apoptosis [6,7,9–11,30]. However, 
the regulation and cellular function of RASSF1C were rarely reported, although several 
studies have debated it is a tumour suppressor or oncogene [6,13–16]. Besides the 
unavailable endogenous anti-RASSF1C antibody, the lack of systemic study on RASSF1C 
is certainly a reason for the absence of this information.
Therefore we addressed this question by generating an anti-RASSF1C antibody and using 
biochemical purification coupled with LC-MS/MS technology. Unfortunately, we produced 
an anti-RASSF1C antibody which can detect ectopically expressed but not endogenous 
RASSF1C protein (see Supplementary Figure S6 at http://www.BiochemJ.org/bj/441/
bj4410227add.htm). Interestingly, RASSF1C affinity purification identified three different 
E3 ligase complexes with high scores, including SCFβ-TrCP, composed of CUL1, Skp1, β-
TrCP1 and β-TrCP2, ROC1-CUL4-DDB1 E3 ligase and a HECT-domain-containing E3 
ligase, Mule. This strongly suggests RASSF1C might be a very unstable protein and 
potentially regulated by polyubiquitylation and proteasome degradation. Consistently, we 
found that the half-life of RASSF1C is approximately 15 min and that the protein is mainly 
degraded via the proteasome. Notably, RASSF1C polyubiquitylation is regulated by stress 
signals including UV damage, doxorubicin treatment, osmotic stress and serum starvation. 
This is the first report that RASSF1C protein levels are regulated via post-translational 
modification.
Via mutant analysis and knockdown experiments, we identified Mule, but not DDB1 or 
SCFβ-TrCP, as the RASSF1C bona fide E3 ligase responsible for the degradation of 
RASSF1C under normal culture conditions. Interestingly, UV-damage-induced RASSF1C 
degradation can be partially blocked by Mule knockdown, indicating that other potential E3 
ligases might also be involved in this process. To our surprise, the S19A/S23A mutant, 
which disrupts the interaction between β-TrCP and RASSF1C, but not DDB1, has a 
comparable effect with Mule under UV irradiation conditions. Taken together, these results 
suggest that Mule controls the polyubiquitylation and degradation of RASSF1C under 
normal conditions, whereas both Mule and SCFβ-TrCP are responsible for RASSF1C 
proteasome degradation in response to UV irradiation (Figure 6).
UV light results in various DNA lesions, including oxidative lesions and DNA single-strand 
breaks [32]. It is worth noting that the SCF complex and Mule function as the other two 
common E3 ligases responsible for protein degradation in response to UV irradiation 
besides CUL4-DDB1, and the target protein degradation is usually controlled by more than 
one E3 ligase. Notably, UV irradiation target proteins such as p21 and Mcl-1 share three 
common features: (i) UV irradiation induces the degradation of both proteins; (ii) GSK3 
phosphorylation leads to polyubiquitylation and degradation; and (iii) UV-induced 
degradation is via two different E3 ligase complexes, p21–SCFSkp2 and CUL4Cdt2, Mcl-1–
SCFβ-TrCP and Mule respectively [29,33–37]. In the present study, we show another 
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example that RASSF1C degradation in response to UV irradiation is controlled by Mule, 
and SCFβ-TrCP and GSK phosphorylation. On the other hand, one can speculate the potential 
role of RASSF1C in DNA repair, cell cycle control and anti-apoptosis from this analogy 
with other target proteins such as p21 and Mcl-1.
As well as its roles in destabilizing growth-stimulating proteins such as cyclin D, cyclin E 
and β-catenin by phosphorylation [38–42], GSK3-regulated proteolysis also plays important 
roles in DNA damage responses. Lee et al. [36] reported that low-dose UV irradiation can 
increase GSK3 activity, and promote the phosphorylation of p21 for rapid degradation via 
proteasome. Another example is that GSK3 phosporylates Mcl-1 in response to UV 
irradiation, and was subsequently polyubiquitylated and degraded by SCFβ-TrCP, but not 
Mule [34]. Therefore phosphorylation of RASSF1C by GSK3 may provide a molecular 
mechanism for RASSF1C destabilization in response to UV irradiation. Consistent with this 
model, UV-irradiation-induced RASSF1C destabilization is significantly blocked by the 
GSK3 inhibitor SB216763. It is worth noting that RASSF1A is also regulated by GSK3β 
[31], and provides us the potential phosphorylation site(s) in RASSF1C.
Activation of the PI3K pathway is frequently observed in human cancers [43,44]. This can 
be achieved by an activating mutation in growth factor receptors and PI3K, or an 
inactivating mutation in PTEN (phosphatase and tensin homologue deleted on chromosome 
10). Increased PI3K signalling results in constitutive Akt activation and GSK3 inhibition. 
Therefore, phosphorylation of RASSF1C by GSK3 may provide a molecular mechanism for 
RASSF1C stabilization by PI3K activation. When PI3K is activated, RASSF1C protein 
levels would accumulate, therefore contributing to the mitogenic activity of the PI3K 
pathway. Conversely, when PI3K signalling activity is low, RASSF1C protein levels would 
decrease, thus leading to apoptosis and growth inhibition. This hypothesis was verified when 
treatment of HeLa cells with serum starvation, which can inactive PI3K, led to the 
degradation of RASSF1C. Although no functional data was obtainable owing to the absence 
of an endogenous antibody, we propose that RASSF1C protein levels may contribute to 
tumorigenesis in cancer cells with dysregulated PI3K signalling.
In the present study, we demonstrated that RASSF1C is a very unstable protein and its 
stability is controlled by the Mule E3 ligase under normal conditions. After DNA damage, 
both Mule and SCFβ-TrCP are involved in the control of RASSF1C proteasome degradation. 
The present study reveals a molecular mechanism of RASSF1C degradation by different E3 
ligases in response to different signals and the regulation of RASSF1C stability by the 
PI3K/Akt/GSK3 pathway. We have provided new insights into the post-translational 
modification of RASSF1C and propose a functional importance in DNA damage responses 
and tumorigenesis in cancer cells with dysregulated PI3K signalling.
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Figure 1. RASSF1C is a very unstable protein and decreases in response to DNA damage
(A) Both cytosolic and nuclear RASSF1C decrease after exposure to UV irradiation. After 
exposure to UV irradiation (40 mJ/cm2) and recovery for 1 h, U2OS stable cells were 
subjected to cytosolic and nuclear fraction extraction as described in the Experimental 
section, and RASSF1C protein levels were determined by Western blot. Tubulin and lamin 
A were used as cytoplasmic and nuclear markers respectively. (B) UV-irradiation-induced 
RASSF1C reduction is faster than the decrease in DAXX. U2OS stable cells were treated 
with UV irradiation (40 mJ/cm2) and recovered for the indicated times. DAXX, RASSF1A 
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and RASSF1C protein levels were detected by Western blot. GAPDH was used as a loading 
control. (C and D) UV irradiation or doxorubicin reduces the protein levels of RASSF1C in 
a time-course-dependent manner. U2OS stable cells were treated with UV irradiation (40 
mJ/cm2) and recovered or treated with doxorubicin (10 µM) for the indicated times. Top 
panel, cell lysates were analysed by Western blot using specific antibodies. Bottom panels, 
relative mRNA levels of RASSF1C were determined by qPCR in the same experiment. (E) 
RASSF1C is an unstable protein. Top panels, HEK-293T stable cells were treated with CHX 
(20 µg/ml) for the indicated times and analysed by Western blot. Bottom panel, the amount 
of RASSF1C was quantified by densitometry and normalized to GAPDH. The ratio between 
RASSF1C and GAPDH at the zero time point was arbitrarily set to 1. (F) MG132 causes the 
accumulation of RASSF1C protein in HEK-293T stable cells. Cells were treated with either 
the solvent DMSO or 10 µM MG132. Top panel, cell lysates were analysed by Western blot. 
Bottom panelm relative RASSF1C levels were normalized to GAPDH and quantified by 
densitometry. (G) RASSF1C is highly polyubiquitylated. FLAG–RASSF1C was 
immunoprecipitated (IP) and polyubiquitylation of the precipitated RASSF1C (RASSF1C–
ubn) was determined by Western blot for the co-transfected HA–ubiquitin (HA-ub).
Zhou et al. Page 16













Figure 2. SCF βTrCP and CUL4-DDB1 are not involved in RASSF1C degradation under normal 
conditions
(A) Silver staining of affinity-purified RASSF1C–containing protein complexes. Cell 
extracts that were prepared from HEK-293T cells stably expressing SBP-FLAG–RASSF1C 
or control cells were subjected to streptavidin affinity purification. Proteins bound to 
streptavidin-conjugated beads from SBP-FLAG–RASSF1C stable cells and control cells 
(VEC) were analysed by SDS/PAGE and visualized by silver staining. Arrows indicate 
RASSF1C and the specific protein bands that interact with it. Molecular mass in kDa is 
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given on the right-hand side. (B) Proteins involved in the degradation of RASSF1C were 
identified by MS analysis. Affinity-purified proteins were identified by MS analysis and the 
detailed peptide sequences are summarized in Tables S1 and S2 (at http://
www.BiochemJ.org/bj/441/bj4410227add.htm). (C) The mutant of the potential 
phosphorylation sites S19A/S23A (S19/23A) disrupts the interaction between RASSF1C 
and β-TrCP. HA–β-TrCP was co-transfected with RASSF1C. FLAG–RASSF1C was 
immunoprecipitated (IP) and the associated HA–β-TrCP was detected by Western blot with 
anti-HA antibody. The RASSF1C S19A/S23A mutant showed weak interaction with β-
TrCP. (D) The binding-deficient mutant of RASSF1C remains an unstable protein. The 
sequences surrounding the phosphodegrons in the N-terminal of RASSF1C are shown. 
Potentially phosphorylated serine residues are shaded (top panel). HA-tagged wild-type 
(WT) or S19A/S23A RASSF1C was cotransfected with GFP (green fluorescent protein), 
which is referred as loading control. At 24 h after transfection, cells were pretreated with 
either the solvent DMSO or 10 µM MG132 for 6 h before harvest, followed by Western blot 
analysis. (E) S19A/S23A mutant does not affect the half-life of RASSF1C. HEK-293T 
stable cells were transfected with the wild-type or S19A/S23A mutant of RASSF1C, and 
then split into 5 different wells. At 24 h after transfection, cells were treated with CHX (20 
µg/ml) for the indicated times. RASSF1C protein levels were determined by Western blot. 
The amount of RASSF1C was quantified by densitometry and normalized with GAPDH. (F) 
β-TrCP overexpression does not result in the increase of characteristic ladders. FLAG–
RASSF1C, HA–ubiquitin (HA-ub) and HA–β-TrCP were cotransfected into cells as 
indicated. Cells were lysed in 1% SDS buffer and subsequently subjected to 
immunoprecipitation and Western blot to detect the polyubiquitin ladders. (G) The S19A/
S23A mutant doesn’t affect RASSF1C polyubiquitylation. FLAG-tagged wild-type or 
S19A/S23A RASSF1C was cotransfected with HA–ubiquitin as indicated, FLAG–
RASSF1C was immunoprecipitated and ubiquitylation of the precipitated RASSF1C was 
detected by Western blot for the co-transfected HA–ubiquitin.
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Figure 3. Mule promotes RASSF1C degradation under normal conditions
(A) Mule interacts with RASSF1C. HA–RASSF1C was co-transfected with FLAG–Mule 
wild-type (WT) or catalytically inactive mutant C4341A (CA). FLAG–Mule was 
immunoprecipitated (IP) and the associated HA–RASSF1C was determined by Western blot 
using an anti-HA antibody. The Mule C4341A mutant showed the same degree of 
interaction. (B) Knocking down Mule leads to accumulation of RASSF1C. Control (si Con) 
or two different Mule (si Mule) siRNA oligonucleotides were transfected into HEK-293T 
cells for Western blot analysis. Both of the Mule siRNAs, but not the control 
oligonucleotide, resulted in dramatic up-regulation of RASSF1C protein (left-hand panel). 
Mule knockdown efficiency was determined by qPCR with specific primers (right-hand 
panel). (C) Mule knockdown significantly increases RASSF1C stability. HEK-293T stable 
cells transfected with Mule siRNA or control oligonucleotides were treated with CHX (20 
µg/ml) for the indicated times. Total protein lysates were subjected to Western blot analysis 
with the indicated antibodies (left-hand panels). The amount of RASSF1C was quantified by 
densitometry and normalized with GAPDH (right-hand panel).
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Figure 4. PI3K/Akt pathway inhibits GSK3 to upregulate RASSF1C protein levels
(A) Calyculin A decreases RASSF1C protein levels. HEK-293T stable cells were treated 
with the serine/threonine phosphatase inhibitor calyculin A (100 nM) for 30 min. RASSF1C 
protein levels were determined by Western blot along with the GAPDH control. (B) 
Calyculin A-induced RASSF1C degradation is blocked by MG132. HEK-293T stable cells 
were treated with or without Calyculin A or MG132 as indicated and RASSF1C protein 
levels were determined. (C) GSK3β inhibitors but not a CK1 inhibitor leads to accumulation 
of RASSF1C proteins. HEK-293T stable cells were treated with the GSK3 inhibitor 
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SB216763 (20 µM) or GSKi IX (2 µM), or the CK1-specific inhibitor IC261 (10 µM) for 4 h 
and RASSF1C protein levels were determined. β-Catenin and TAZ served as positive 
controls respectively. (D) GSK3β binds to RASSF1C. HA–GSK3β was co-transfected with 
FLAG–RASSF1C and co-immunoprecipitation (IP) was performed to determine the 
interaction between RASSF1C and GSK3β. The associated HA–GSK3β was detected by 
Western blot. (E) GSK3β induces proteasome-dependent degradation of RASSF1C. HA–
GSK3β was transfected into HEK-293T stable cells, followed by treatment with 10 µM 
MG132 for 6 h and then RASSF1C protein levels were determined. (F) Inhibition of PI3K 
reduces RASSF1C protein levels in a dose-dependent manner. HEK-293T stable cells were 
treated with the PI3K inhibitor LY294002 as indicated for 6 h and then cell lysates were 
analysed by Western blot. (G) Inhibition of PI3K induces proteasome-dependent RASSF1C 
degradation. HEK-293T stable cells were treated with or without the PI3K inhibitor 
LY294002 (40 µM) or MG132 (10 µM) for 6 h as indicated, and RASSF1C protein levels 
were determined. (H) GSK3 inhibitor blocks RASSF1C degradation induced by PI3K 
inhibition. HEK-293T stable cells were treated with or without the PI3K inhibitor 
LY294002 (50 µM), wortmannin (1 mM) or the GSK3 inhibitor SB216763 (20 µM) for 6 h 
as indicated. Cell lysates were analysed by Western blot. (I) The GSK3 inhibitor SB216763 
disrupts the interaction between Mule and RASSF1C. HA– RASSF1C was co-transfected 
with FLAG–Mule. At 24 h post-transfection, cells were treated with or without SB216763 
(20 µM). FLAG–Mule was immunoprecipitated (IP) and the associated HA–RASSF1C was 
detected by Western blot analysis.
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Figure 5. DNA damage promotes the degradation of RASSF1C via Mule and SCF βTrCP
(A) MG132 blocks UV irradiation or doxorubicin (DOX)-induced RASSF1C decrease. 
U2OS stable cells were treated with or without UV irradiation or doxorubicin, combined 
with or without MG132 as indicated. RASSF1C protein levels were determined by Western 
blot analysis. (B) UV irradiation and doxorubicin treatment promote RASSF1C 
polyubiquitylation. FLAG-tagged RASSF1C was cotransfected with HA–ubiquitin (HA-ub) 
as indicated, and 24 h after transfection, cells were treated with or without UV irradiation 
(40 mJ/cm2, recovery for 2 h) or doxorubicin (10 µM, 6 h). FLAG–RASSF1C was 
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immunoprecipitated and polyubiquitylation of the precipitated RASSF1C was determined by 
Western blot for the co-transfected HA–ubiquitin. (C) RASSF1C is primarily degraded in 
the nucleus. U2OS stable cells were exposed to UV irradiation with or without MG132. 
Cytosolic and nuclear fractions were prepared as described in the Experimental section, and 
then subjected to Western blot analysis. Tubulin and lamin A were used as markers for the 
cytoplasm and nucleus respectively. (D) UV irradiation promotes the interaction between 
Mule (top panel) or β-TrCP (bottom panel) and RASSF1C. RASSF1C was co-transfected 
with Mule or β-TrCP into U2OS cells as indicated. At 24 h after transfection, cells were 
treated with or without UV irradiation (40 mJ/cm2, recovery for 2 h). FLAG–Mule or 
FLAG–RASSF1C was immunoprecipitated (IP) and the associated HA–RASSF1C or HA–
β-TrCP was analysed by Western blot respectively. (E) Mule knockdown blocks UV-
irradiation-induced RASSF1C degradation. U2OS stable cells transfected with Mule siRNA 
or control oligonucleotides were treated with UV irradiation (40 mJ/cm2) and recovered for 
the indicated times. Total protein lysates were subjected to Western blot with the indicated 
antibodies (top panels). The RASSF1C protein levels were quantified by densitometry and 
normalized to GAPDH (bottom panel). (F) The S19A/S23A (S19/23A) mutant dramatically 
disrupts UV-induced degradation of RASSF1C. U2OS cells were transfected with wild-type 
(WT) or S19A/S23A mutant of RASSF1C, and then split into four different wells. At 24 h 
after transfection, cells were treated with UV irradiation (40 mJ/cm2) and recovered for the 
indicated times. RASSF1C protein levels were determined by Western blot analysis. The 
amounts of RASSF1C were quantified by densitometry and normalized to GAPDH. (G) 
UV-irradiation-induced RASSF1C degradation can be blocked by the GSK3 inhibitor 
SB216763. U20S stable cells were treated with or without UV irradiation (40 mJ/cm2, 
recovery for 2 h), coupled with or without SB216763 (20 µM) as indicated. RASSF1C 
protein levels were determined by Western blot.
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Figure 6. A model depicting the postulated Mule and SCF βTrCP-mediated degradation of 
RASSF1C in response to DNA damage
Mule, a HECT family E3 ligase, promotes RASSF1C degradation under normal conditions, 
whereas both Mule and SCFβ-TrCP target RASSF1C degradation in response to UV 
irradiation. p, phosphorylation; ub, ubiquitin.
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